BERKELEY, CA (UroToday.com) - Randomized controlled trials (RCTs) show that six targeted agents – sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab and pazopanib – improve outcome in advanced renal cell carcinoma (RCC).

To read more, a FREE Urotoday registration is required. Click here to register or login above.
To read UIJ content, a separate subscription is required.